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Edited by Michael R. BubbAbstract Malignant mesothelioma (MM) cells enhanced prolif-
eration of endothelial cells (ECs) as well as their angiogenesis
in vitro by secretion of ﬁbroblast growth factor-2 (FGF2). This
eﬀect was suppressed by pre-treating MM cells with a-toco-
pheryl succinate (a-TOS), which inhibited FGF2 secretion by
inducing mitochondria-dependent generation of reactive oxygen
species. The role of FGF2 was conﬁrmed by its down-regulation
by treating MM cells with siRNA, abolishing EC proliferation
and wound healing enhancement aﬀorded by MM cells. We con-
clude that a-TOS disrupts angiogenesis mediated by MM cells
by inhibiting FGF2 paracrine signalling.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Tumour progression is dependent on formation of new
blood vessels supplying cancer cells with oxygen and nutrients.
Endothelial cells (ECs) are forced to re-enter the cell cycle dur-
ing tumour progression to form new blood vessels [1,2]. Cancer
cells secrete growth factors, including the vascular endothelial
(VEGF) and ﬁbroblast growth factors (FGF), that interact
with corresponding receptors on ECs, promoting their prolif-
eration [3]. As angiogenesis is essential for tumour progression,
its suppression represents an intriguing anti-cancer strategy.
Gene therapy, immunotherapy or chemotherapy have been a
recent focus to inhibit angiogenesis [4–6].
We and others have shown that compounds like the mitocan
a-tocopheryl succinate (a-TOS), a redox-silent analogue of
vitamin E (VE) [7] and a potent inhibitor of cancer in pre-clin-
ical models [8,9], also disrupts mitogenic signalling pathways
[10,11]. These include the ﬁbroblast growth factor-2 (FGF2)Abbreviations: DCF, dihydrodichloroﬂuorescein diacetate; EC, endo-
thelial cell; FGF2, ﬁbroblast growth factor-2; MM, malignant meso-
thelioma; NS, non-silencing; RNAi, RNA interference; ROS, reactive
oxygen species; siRNA, short interfering RNA; a-TOS, a-tocopheryl
succinate; VE, vitamin E
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doi:10.1016/j.febslet.2007.08.051autocrine loop, by means of which cancer cells control their
own proliferation [12]. We have shown that a-TOS suppressed
expression of FGF2 by inhibiting the transcriptional activity of
egr-1 [10] as well as down-regulating the cognate FGF2 recep-
tor FGFR1, probably by impairing the activity of E2F1 [11].
As FGF2 is an important mitogen driving EC proliferation
[12], we hypothesised that a-TOS could also suppress angio-
genesis by inhibiting FGF2 expression in malignant mesotheli-
oma (MM) cells, whereby disrupting the paracrine signalling
pathway, as documented in this communication.2. Materials and methods
2.1. Cell culture
Human MM cell lines, MM-B1, Meso-2, and Ist-Mes2 [13], and a
non-malignant mesothelial cell line, Met-5A (ATCC), were cultured
in DMEM supplemented with 10% FCS (both JRH Biosciences),
2 mM L-glutamine and antibiotics. Endothelial-like EAhy926 cells
[14] were maintained in DMEM supplemented with HAT (100 lM
hypoxanthine, 0.4 lM aminopterin, 16 lM thymidine). The cells retain
the properties of primary ECs, including expression of factor VIII and
P-selectin [14], tube-forming activity and the propensity to persist in
conﬂuent cultures [4].2.2. Cell proliferation
Cell proliferation was assessed using an ELISA kit (Roche) to deter-
mine cells in the S-phase, based on 5-bromo-2-deoxyuridine (BrdU)
DNA incorporation. EAhy926 cells were seeded at 104 cells/well into
a 96-well plate, treated, and incubated with 10 lM BrdU for 2 h at
37 C. The cells were ﬁxed and denatured with Fixdenat (Boehringer
Mannheim), incubated with anti-BrdU IgG, and further incubated
with tetramethylbenzidine. One mole of H2SO4 was then added to stop
the reaction, and the absorbance was read at 450 nm.2.3. Detection of reactive oxygen species (ROS)
Following treatment, cells were reacted with dihydrodichloroﬂuores-
cein diacetate (DCF; Molecular Probes) and scored by ﬂow cytometry
for cells with high ﬂuorescence as described [10]. In some experiments,
cells were pre-treated for 1 h with 2 lMmitochondrially targeted coen-
zyme Q (MitoQ) [15].2.4. Transwell experiments
Co-culture experiments were performed using the clear Transwell
supports (0.4 lm pore, 6.5 mm diameter) in a 24-well conﬁguration
(Corning). EAhy926 cells were seeded (5 · 105/well) in the 12 central
wells, overlaid with 0.6 ml of media, and allowed to adhere. Inserts
were seeded with MM cells (105/insert), ﬁrst in the outer wells of the
plate where they were pre-treated with 25 lM a-TOS for 12 h. The
inserts were then transferred to the central wells containing ECs and
overlaid with 0.1 ml media. Proliferation of the EAhy926 cells was as-
sessed 12 h later.blished by Elsevier B.V. All rights reserved.
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Fig. 1. a-TOS suppresses MM-mediated EC proliferation. EAhy926
cells were seeded in 24-well plates and left to reach 50% conﬂuency.
The cells were then allowed to proliferate following addition of 1 ml
media conditioned with Ist-Mes2, Meso-2, MM-BI, MCF-7 or Met5A
cells pre-treated with a-TOS (25 lM, 24 h) for 12 h, at which stage
their proliferative rate was assessed as speciﬁed in Section 2.
4612 J. Neuzil et al. / FEBS Letters 581 (2007) 4611–46152.5. Analysis of FGF1 and FGF2 protein
FGF1 and FGF2 protein levels were assessed using an ELISA kit
(R&D Systems) according to the manufacturer’s instructions. Cells
were seeded in 24-well plates and allowed to reach 60–70% conﬂuence.
Following treatment, 100 ll of cell-conditioned medium was trans-
ferred to the ELISA plate, mixed with 100 ll of the diluent and incu-
bated at room temperature. After washing, each well was supplemented
with the FGF conjugate, which was followed by incubation at room
temperature with the substrate solution. Absorbance at 450 nm was
read. The system was calibrated using hrFGF1 or hrFGF2.
2.6. RNA interference (RNAi)
Cells were seeded at 5 · 104/well in 12-well plates, allowed to reach
50% conﬂuence and exposed to FGF1 or FGF2 short interfering
RNA (siRNA) (Proligo) as follows: siRNA (0.5 lg/ml) was combined
with 100 ll serum-free DMEM supplemented with 20 ll of OligofectA-
mine (Invitrogen) and left for 15 min at room temperature. The trans-
fection mixture was added to cells, which were then left in the
incubator for 24 h, after which they were overlaid with complete
DMEM. The cells were used in experiments 48 h later. Typically,
90–95% of treated cells showed signiﬁcant down-regulation of the tar-
get genes as estimated by ﬂow cytometric analysis (data not shown).
Non-silencing RNA was used as a negative control and FITC-tagged
non-speciﬁc RNA as a control for transfection eﬃcacy (both Qiagen).
2.7. Wound healing experiments
EAhy926 cells were seeded in 35-mm Petri dishes and allowed to
reach complete conﬂuency. The monolayer was ‘wounded’ by removal
of cells, generating a denuded region 0.5 mm wide. Re-growth in theIn
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Fig. 2. a-TOS suppresses cancer cell-mediated angiogenesis in vitro. EAhy9
conﬂuence. The EC monolayer was ‘injured’ by denudation of central region
allowed to re-grow in the absence (Ctrl) or presence of conditioned media
treated (M+T) or not (M) with 25 lM a-TOS for 24 h prior to media withdra
the denuded zone in a phase contrast microscope ﬁtted with a grid in the objec
absence and presence of conditioned media from cancer cells obtained by per
F shows EAhy926 cells at times 0 and 18 h following injury in the absence (C
(M+T) or not (M) with a-TOS.presence of a-TOS was assessed by following the time-dependent nar-
rowing of the denuded region using a microscope equipped with a grid
in the eyepiece, and the healing rate was expressed in lm/h.B
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26 cells were seeded in 35-mm Petri dishes and left to reach complete
of the endothelium (0.5 mm wide cell-free zone). The cells were then
from Ist-Mes2 (A), Meso-2 (B), MM-BI (C) or Met-5A cells (D) pre-
wal. Kinetics of injury healing was assessed by measuring the width of
tive. Panel E documents the ‘healing rate’ (in lm/h) for EAhy926 in the
forming linear regression on the re-growth curves in panels A–D. Panel
trl) and presence of conditioned media from Ist-Mes2 cells pre-treated
J. Neuzil et al. / FEBS Letters 581 (2007) 4611–4615 46132.8. Statistics
The data shown are mean values ± S.D. derived from at least three
independent experiments. Statistical diﬀerences were calculated using
the Student’s t-test, and diﬀerences were considered signiﬁcantly diﬀer-
ent at P < 0.05.Pr
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Fig. 3. Co-culture of endothelial cells with cancer cells stimulates their
growth, and this is suppressed by a-TOS. EAhy926 cells were seeded at
5 · 105/well in the bottom compartments of the 24-well Transwell
plate. Untreated cancer cells or cells pre-treated with a-TOS (12 h,
25 lM) were seeded in the upper compartment of the corresponding
wells of the Transwell plate (105 per well), and the proliferative status
of ECs was assessed 12 h later using the BrdU assay.3. Results and discussion
We have reported that a-TOS suppressed expression of cyto-
kines, such as FGF1, FGF2 and TGFb, but not VEGF, in
MM cells, whereby impairing their autocrine-dependent prolif-
erative signalling pathways [10]. Since cytokines like FGF2 are
potent mediators of paracrine angiogenic signalling [12] and
since angiogenesis is essential for progression of MM [16],
we studied whether a-TOS also suppresses angiogenesis by
impairing secretion of FGF1 and FGF2 by MM cells.
Since angiogenic cytokines are soluble proteins secreted by
cancer cells, we ﬁrst investigated whether media from MM cul-
tures stimulate proliferation of ECs. Fig. 1 shows that the level
of proliferation of EAhy926 cells increased by 50–60% when
ECs were supplemented with conditioned media from MM
cell, but not from the non-malignant mesothelial Met-5A cells.
The stimulatory eﬀect was abolished when the MM cells were
pre-treated with sub-apoptotic levels of a-TOS.
We next studied the eﬀect of conditioned media on an
in vitro angiogenesis model, which is based on wound healing.
Following removal of a stripe of conﬂuent EC cultures,
re-growth was followed on the basis of ‘closing the gap’, and
the rate of wound healing was expressed in lm/h. Fig. 2 shows
that conditioned media from MM cell cultures enhanced the
would-healing process by 60–90%, from 20 lm/h to 35–
40 lm/h. No eﬀect of media from Met-5A cell cultures was ob-D
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Fig. 4. a-TOS suppresses FGF2 secretion by cancer cells due to oxidative stre
plates and exposed to 25 lM a-TOS for 3 (A) or 24 h (B, C), following a 30-
then assessed for generation of ROS using the DCF assay (A) and for FGF
wound healing of EAhy926 cultures following, as shown, addition of conditio
following 30-min pre-treatment with 2 lM MitoQ.served. Media from MM cells pre-treated with sub-apoptotic
doses of a-TOS failed to enhance angiogenesis in vitro.
The above data suggest presence of soluble compounds, se-
creted by MM cells, that enhance EC proliferation and wound
healing. We therefore subjected ECs to co-culture with MM
and Met-5A cells in Transwell plates. Fig. 3 documents that
presence of the MM cells enhanced proliferation of ECs in
the co-cultures by 50%. This was partially abolished when
MM cells were pre-treated with a-TOS. Met-5A cells did notFG
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Fig. 5. Down-regulation of FGF2 suppresses the angiogenesis stim-
ulatory eﬀect of cancer cells. Ist-Mes2 or MM-BI cells were treated, as
shown, for 48 h with FGF2 or FGF1 siRNA as well as non-silencing
siRNA, and assessed for the level of FGF2 and FGF1 (with FGF
levels of control cells set at 100%) (A). EAhy926 cells were seeded so
that they acquired 50% conﬂuency (B), or in 35-mm Petri dishes,
allowed to reach conﬂuence and subjected to injury as detailed in
Section 2 (C). The eﬀect of media conditioned with Ist-Mes2 and
Meso-2 pre-treated with the siRNA as shown on proliferation (B) and
wound healing (C) was assessed.
4614 J. Neuzil et al. / FEBS Letters 581 (2007) 4611–4615stimulate proliferation of ECs in the co-culture experiments.
We next tested the eﬀect of hrFGF1 and hrFGF2 on ECs
and found very little eﬀect of FGF1, while FGF2 enhanced
EC proliferation by 50% and wound healing by more than
100% (data not shown).
Recent data document that a-TOS suppresses expression of
FGF1 and FGF2 by causing oxidative stress in MM cells,
resulting in generation of mitochondria-derived superoxide
[10]. This is conﬁrmed in Fig. 4, showing that accumulation
of ROS in MM cells as a response to a-TOS was suppressed
by pre-treatment with MitoQ. Met-5A cells did not respond
to the VE analogue by ROS accumulation, which may explain
their lack of FGF1/2 down-regulation upon stimulation with
a-TOS. MitoQ also restored the levels of secreted FGF1 and
FGF2 by MM cells, suppressed by a-TOS, and inhibited angi-
ogenesis in vitro promoted by MM cell-conditioned media and
reversed the inhibitory eﬀect of a-TOS on the wound healing-
promoting activity of MM cell-conditioned media.
To conﬁrm the role of FGF2 paracrine signalling on EC
proliferation and angiogenesis in vitro, we treated MM cells
with FGF2 siRNA. Fig. 5A reveals that this resulted in much
lower secretion of FGF2 by the cells, similarly as observed for
FGF1 using FGF1 siRNA. Media from FGF2 siRNA (but
not FGF1 siRNA)-treated cells suppressed the enhancing
eﬀect of MM cell-conditioned media on EC proliferation and
angiogenesis in vitro.
In this communication we report on a novel activity of an
anti-cancer agent, a-TOS, which is presented by its anti-angio-
genic eﬀect due to disruption of paracrine signalling. This work
follows our previous paper showing suppression of FGF2
expression by a-TOS, whereby inhibiting the autocrine prolif-
erative signalling of MM cells [10]. The VE analogue exerted
its eﬀect by promoting generation of ROS by the cells, which
resulted in inhibition of the activity of the transcription factor
egr-1 that controls expression of FGF2 [10,17].
As FGF2 is an important angiogenic factor [3,12], we
expected that down-regulation by a-TOS of the cytokine in
cancer cells may result in inhibition of EC proliferation. We
observed this and, moreover, it appears that the eﬀect is due
to generation of ROS by the VE analogue in MM cells. This
is documented using MitoQ that is known to inhibit oxidative
stress by accumulating in the mitochondrial inner membrane,
its redox-active head-group reaching the coenzyme Q binding
site(s) in complex II [18]. We have recently documented that
ROS are generated by cancer cells in response to a-TOS due
to displacement of coenzyme Q from complex II by the VE
analogue [19]. This is likely the reason for the toxicity of the
agent, including modulation of the transcriptional activity
[10,11], and this can also explain the novel activity of a-TOS
reported here.
Malignant mesothelioma is an exceedingly diﬃcult type of
cancer, resisting established treatments. Novel strategies are
being sought, including immunotherapy and gene therapy
[20]. Inhibition of angiogenesis appears to be a viable mode
of mesothelioma suppression, and small anti-angiogenic agents
are currently trialed [20]. Our work suggests that a-TOS is of
substantial promise to be used as anti-mesothelioma drug,
since it suppresses MM by at least several independent mech-
anisms. These include direct induction of apoptosis in MM
cells [21], inhibition of MM cell proliferation by disrupting
the paracrine signalling pathway [10,11], and suppression of
the angiogenic paracrine FGF2 signalling reported here.Acknowledgements: The authors thank Prof. R. Smith for donation of
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